CopyMark Law Group
4.9/5
Drawing for TCANCER

USPTO serial 79437944

TCANCER

Reviewed by CopyMark Law Group

Reg. 8309564Status 700Registered
Filing date
Status date
Registration date
Jun 23, 2026
Examiner
CROWDER-SCHAEFER, ANDREW W
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with TCANCER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nicholas D. Wells

Nicholas D. Wells Legends Law Group, PLLC330 Main St.Kaysville, UT 84037United States

Goods and services

ClassDescriptionStatusFirst use
005Chemical products in the nature of chemical reagents for medical diagnosis; diagnostic preparations for medical use through using t-cell receptors (tcrs); diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations; diagnostic reagents for medical and veterinary use in in vitro diagnosis; diagnostic substances for medical use; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, individual medical diagnosis; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, tumour identification; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection in oncology; diagnostic test reagents comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection for veterinary use; indicators for medical diagnosis, namely, diagnostic preparations for medical use in vivo diagnosis; medical diagnostic reagents; medical preparations for the treatment of cancer; pharmaceutical drugs in the nature of preparations for the treatment and prevention of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment and prevention of cancer; pharmaceutical preparations for diagnosis, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for diagnostic purposes, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for individual medical diagnosis, namely, diagnostic agents for pharmaceutical purposes; pharmaceutical preparations for medical purposes for the treatment and prevention of cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in cancer diagnosis; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for individual medical diagnosis in the nature of disease detection of cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in oncology for testing of bodily fluids for use in cancer; pharmaceutical preparations for medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer; pharmaceutical preparations for suppressing tumours; pharmaceutical preparations, namely, protein arrays for medical diagnosis purposes for the diagnosis of diseases; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for treating cancer; pharmaceutical products, medical and veterinary preparations, namely, diagnostic preparations for medical or veterinary purposes; pharmaceuticals products for the treatment of cancer; pharmaceutical products for treating cancer; preparations for medical diagnosis, namely, diagnostic preparations for medical use in vivo diagnosis; reactants for medical diagnosis, namely, diagnostic preparations for medical use in in vivo diagnosis; reagents and preparations for use in the nature of diagnostic test reagents for medical purposes; reagents for diagnostic tests for medical use; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for profiling, in particular genomic and proteomic profiling, for use in the selection of therapeutics for cancer patients; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for the diagnosis of diseases in the nature of cancer; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptors (tcrs) for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptors (tcrs) for oncological purposes for treating cancer; medical tests and medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection of cancer using t-cell receptor (tcr) clusters for oncological purposes; pharmaceutical preparations and medical reagents using t-cell receptor (tcr) clusters for oncological purposes for treating cancer; tumour suppressing agents; immunomodulators, namely, pharmaceutical preparations for treatment of cancer; immunostimulants; immunotherapeutic agents, namely, pharmaceutical preparations for treatment of cancer; pharmaceutical products in the nature of preparations for the treatment of autoimmune diseases and autoimmune disorders, pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of immune system related disordersACTIVE—
035Maintenance of data in computer databases featuring medical patient information; maintenance of data in computer databases featuring oncological information; maintenance of data in medical computer databases; maintenance of data in computer databasesACTIVE—
042Blood analysis services for scientific purposes; development of database services featuring medical patient information; development of database services featuring oncological information; development of database services featuring sequenced t-cell receptors (tcrs); development of medical database services; development of database services; development of pharmaceutical preparations and medicines; research laboratory services in the medical field; maintenance of online databases for others; medical research in the field of immunology, oncology, infectiology and vaccines; medical research services, namely, performing analyses for medical research; performing chemical analyses; platform as a service (PAAS) featuring computer software platforms for use in database management and t-cell receptor (tcr) identification and characterisation; research and development of pharmaceutical preparations for treating malignant tumours; research of pharmaceuticals; research services in the field of medical analyses and diagnostics; scientific research and development in identification of tumour antigens; scientific research and development in the field of immunology, oncology, infectiology and vaccines; scientific research and development in the field of t-cell receptors (tcrs); scientific research and development; software as a service (SAAS) featuring software for database management and use in t-cell receptor (tcr) identification and characterisation; scientific research and development services for medical and pharmaceutical purposes in the fields of immunology, oncology, infectiology and vaccines; research and development services in connection with pharmaceutical and medical preparations, medicine and pharmaceuticals in the fields of immunology, oncology, infectiology and vaccines; computerised medical evaluation and diagnostic services in the nature of medical research services in the fields of immunology, oncology, infectiology and vaccinesACTIVE—
044Healthcare services, namely, computerised medical evaluation and diagnostic services in the fields of immunology, oncology, infectiology and vaccines; healthcare services, namely, computerised medical diagnostic services in the fields of immunology, oncology, infectiology and vaccinesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 23, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 9, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 23, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jun 23, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 5, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 5, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 30, 2026GPNXNOTIFICATION PROCESSED BY IB—
Apr 29, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 15, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 15, 2026OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Apr 3, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 1, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 1, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 1, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 5, 2026RFNTREFUSAL PROCESSED BY IB—
Jan 18, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 18, 2026RFRRREFUSAL PROCESSED BY MPU—
Dec 11, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 10, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 3, 2025DOCKASSIGNED TO EXAMINER—
Dec 2, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 2, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 27, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance